Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/
MOSS!MODULARITY Injection Screw
MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.:
- Improved visualisation and access to the surgical working space;
- Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads;
- Increased surgical versatility, as surgeons can choose between different types of modular screw shafts and various tulip heads to be added to the screw shafts in-situ as and when required.
Breaking new ground, Biedermann Motech will now introduce the MOSS!MODULARITY Injection Screw to selective markets outside the U.S. Fenestrated injection pedicle screws for spinal surgery, which Biedermann Motech has been pioneering since 2003, enable the injection of bone cement through the screw to enhance fixation in compromised bone1. The new injection screw workflow allows surgeons to insert the headless screw shaft directly into the bone, using the injection adaptor as the screw inserter, and then seamlessly inject bone cement before attaching the modular tulip heads to the screw shaft. The MOSS!MODULARITY Injection Screw workflow features proprietary technology licensed from intellectual property powerhouse and recognized innovation leader Biedermann Technologies GmbH & Co. KG and will be the first of its kind worldwide.
Simultaneously, Biedermann Motech will launch the next generation of its DELTA XS ® Retractor System for advanced Transforaminal Lumbar Interbody Fusion (“TLIF”) surgery. The DELTA XS 2.0 Retractor System has been specifically developed to combine the advantages of a screw shank based retractor with the benefits of the MOSS!MODULARITY workflow and can be used in a variety of surgical techniques and approaches, from open to less invasive, microsurgical TLIF surgery.
The MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System are fully compatible with the MOSS 100 Modular Pedicle Screw System, the MOSS VRS System and the MOSS VRS MIS System for advanced posterior fixation and correction and will further strengthen these platforms for specialized spinal surgery.
Biedermann Motech will showcase the worldwide first MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System at the upcoming Eurospine Meeting in Copenhagen, Denmark.
ABOUT BIEDERMANN MOTECH & BIEDERMANN TECHNOLOGIES
Biedermann is a mid-sized, family-owned group of companies, whose roots go back to 1916. Biedermann researches, develops, manufactures, and distributes high-end implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. It is also owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 30 years, Biedermann has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field and established multiple new golden standards for spinal technologies.
For more information, please visit:
www.biedermann.com and www.biedermann-technologies.com
1 J Orthop Traumatol. 2011 Nov 8;12(4):193–199; Int J Spine Surg. 2021 Feb 26;15(1):113–118.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251019799867/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 11:00:00 CEST | Press release
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK20.10.2025 10:01:00 CEST | Press release
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch
Leading Global Businesses Unite to Launch Carbon Measures20.10.2025 10:00:00 CEST | Press release
New coalition to advance global carbon accounting framework and champion market-based solutions that drive emissions reductionsAmy Brachio, former Ernst & Young global vice chair and head of sustainability, named CEO Carbon Measures, a new global coalition representing major businesses from diverse industries and geographies, launched today to establish a more accurate carbon accounting framework and drive market-based solutions to reduce emissions at the lowest cost. The coalition’s work will leverage sound science and the principles of financial accounting to help enable a ledger-based carbon accounting framework that is substantially more accurate, eliminates double counting and addresses current information gaps. By better tracking emissions through the global economy, this new framework will help businesses differentiate their products and governments make more informed policy decisions. Carbon Measures is calling for new policy that unlocks innovation, competition and the power o
Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal20.10.2025 09:00:00 CEST | Press release
Valeo Foods Group, one of Europe's leading producers of quality sweets, treats and snacks has been awarded a Platinum Medal, the highest recognition level, in the EcoVadis sustainability assessment. Valeo Foods now ranks among the top one percent of companies evaluated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020547491/en/ Valeo Foods Group recognised for sustainability leadership with EcoVadis Platinum Medal. Ronald Kers, Valeo Foods Group CEO said “Achieving EcoVadis Platinum rating is a proud moment for our business. It reflects the dedication of our people and our determination to integrate sustainability into everything we do – from how we source and produce, to how we support communities and protect the planet.” Dr Grainne O’Halloran, Head of Sustainability at Valeo Foods added: “We are incredibly proud to have achieved EcoVadis Platinum Medal this year. Our increased score reflects our ongoing commitment to
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 08:00:00 CEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom